BiotechTube

V503 + GARDASIL

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Papilloma Viral Infection

Conditions

Papilloma Viral Infection

Trial Timeline

Mar 24, 2014 → Apr 22, 2015

NCT ID
NCT02114385

About V503 + GARDASIL

V503 + GARDASIL is a phase 3 stage product being developed by Merck for Papilloma Viral Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT02114385. Target conditions include Papilloma Viral Infection.

What happened to similar drugs?

5 of 20 similar drugs in Papilloma Viral Infection were approved

Approved (5) Terminated (0) Active (15)
✅Zopapogene imadenovec (Zopa)PrecigenApproved
✅Human Papillomavirus 9-valent Vaccine, RecombinantMerckApproved
✅GardasilMerckApproved
✅Gardasil-9MerckApproved
✅Human papillomavirus 9-valent vaccine, recombinant + human papillomavirus vaccine, recombinantMerckApproved
🔄9vHPV vaccineMerckPhase 3
🔄V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)MerckPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT03998254Phase 3Active
NCT02653118Pre-clinicalActive
NCT02114385Phase 3Completed
NCT01304498Phase 3Completed

Competing Products

20 competing products in Papilloma Viral Infection

See all competitors
ProductCompanyStageHype Score
Zopapogene imadenovec (Zopa)PrecigenApproved
44
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2PrecigenPhase 1/2
30
AAVLP-HPV + Placebo2A PharmaPhase 1
19
Lenvatinib + PembrolizumabEisaiPhase 1
36
9vHPV vaccineMerckPhase 3
44
GardasilMerckPre-clinical
22
Human Papillomavirus 9-valent Vaccine, RecombinantMerckApproved
43
V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)MerckPhase 3
40
V503 + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-Concomitant) + Comparator: Adacel™ (Non-concomitant)MerckPhase 3
40
Quadrivalent human papillomavirus vaccine on-time administration + Quadrivalent human papillomavirus vaccine delayed administrationMerckPre-clinical
26
GardasilMerckApproved
43
quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccineMerckPhase 3
36
GardasilMerckPhase 2
35
9vHPV VaccineMerckPhase 3
44
Octavalent HPV with 15 mcg IMX / AAHS + Octavalent HPV with 30 mcg IMX / AAHS + Octavalent HPV with 60 mcg IMX / AAHS + Octavalent HPV with 120 mcg IMX / AAHS + Comparator: Quadrivalent HPV Vaccine (qHPV), (GARDASIL™)MerckPhase 1
29
9vHPV Vaccine + mRNA-1273 VaccineMerckPhase 3
40
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant VaccineMerckPhase 3
40
V501MerckPhase 3
40
V503 + GARDASILMerckPhase 3
40
9vHPV VaccineMerckPhase 3
44